• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Enovis Corporation

    5/21/25 4:07:27 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    8-K
    Enovis CORP false 0001420800 0001420800 2025-05-21 2025-05-21
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 21, 2025

     

     

    Enovis Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-34045   54-1887631
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    2711 Centerville Road, Suite 400
    Wilmington, DE 19808
    (Address of principal executive offices) (Zip Code)

    (302) 252-9160

    (Registrant’s telephone number, including area code)

    Not applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On May 21, 2025, Enovis Corporation (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which three proposals were submitted to the Company’s stockholders. The proposals are described in detail in the Company’s Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 11, 2025. The final results for each proposal are set forth below:

    Proposal 1- Election of Directors:

    The Company’s stockholders elected nine directors to the Board (to hold office until the next annual meeting of stockholders and until their respective successors are elected and qualified). The votes regarding this proposal were as follows:

     

    Nominee

       For      Against      Abstain      Broker Non-Votes  

    Barbara W. Bodem

         50,389,032        46,982        41,228        1,714,700  

    Liam J. Kelly

         50,361,887        71,570        43,785        1,714,700  

    Angela S. Lalor

         50,246,980        189,025        41,237        1,714,700  

    Philip A. Okala

         50,388,477        47,399        41,366        1,714,700  

    Christine Ortiz

         50,371,680        52,528        53,034        1,714,700  

    A. Clayton Perfall

         49,602,784        833,018        41,440        1,714,700  

    Brady Shirley

         50,046,653        389,413        41,446        1,714,700  

    Rajiv Vinnakota

         49,629,719        806,216        41,307        1,714,700  

    Sharon Wienbar

         50,129,644        306,543        41,055        1,714,700  

    Proposal 2- Ratification of appointment of independent registered accounting firm:

    The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The votes regarding this proposal were as follows:

     

    For

      

    Against

      

    Abstain

    51,602,749    546,062    43,131

    Proposal 3- Advisory vote on the executive compensation of the named executive officers:

    The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:

     

    For

      

    Against

      

    Abstain

      

    Broker Non-Votes

    49,556,825    872,557    47,860    1,714,700


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: May 21, 2025

     

    ENOVIS CORPORATION
    By:  

    /s/ Bradley J. Tandy

    Name:   Bradley J. Tandy
    Title:   Senior Vice President and
      Chief Legal Officer
    Get the next $ENOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings